Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 111, Issue -, Pages 87-93Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2017.01.011
Keywords
Myeloma; Immunotherapy; Monoclonal antibody; Dendritic cell; T cell
Categories
Funding
- Leading Foreign Research Institute Recruitment Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science, and Technology (MEST) [2011-0030034, 2015R1D1A1A09057809]
- Korea Health Technology RAMP
- D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health AMP
- Welfare, Republic of Korea [HI14C1898]
- National Research Foundation of Korea [2015R1D1A1A09057809] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Immunotherapy has recently emerged as a promising treatment for multiple myeloma (MM). There are now several monoclonal antibodies that target specific surface antigens on myeloma cells or the checkpoints of immune and myeloma cells. Elotuzumab (targeting SLAMF7), daratumumab (targeting CD38), and pembrolizumab (targeting PD-1) have shown clinical activity in clinical studies with relapsed/refractory MM. Dendritic cell vaccination is a safe strategy that has shown some efficacy in a subset of myeloma patients and may become a crucial part of MM treatment when combined with immunomodulatory drugs or immune check-point blockade. Genetically engineered T cells, such as chimeric antigen receptor T cells or T cell receptor-engineered T cells, have also shown encouraging results in recent clinical studies of patients with MM. In this paper, we discuss recent progress in immunotherapy for the treatment of MM. (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available